Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sudarshan Pharma IndustriesBOM:543828 -5.00%69 Return-on-Tangible-Equity is 30.40% as of Mar. 2026, which is 139% above its 10-year median of 12.70. GuruFocus rates BOM:543828 with a GF Score™ of 69/100 and a GF Value™ of ₹6.52 (Significantly Overvalued). The stock has 14 warning signs investors should review. Among 1,570 Chemicals companies, Sudarshan Pharma Industries ranks better than 85.29% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Sudarshan Pharma Industries's annualized net income for the quarter that ended in Mar. 2026 was ₹429 Mil. Sudarshan Pharma Industries's average shareholder tangible equity for the quarter that ended in Mar. 2026 was ₹1,411 Mil. Therefore, Sudarshan Pharma Industries's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 30.40%.
The historical rank and industry rank for Sudarshan Pharma Industries's Return-on-Tangible-Equity or its related term are showing as below:
BOM:543828'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 4.89 Med: 12.7 Max: 20.21
Current: 17.28
During the past 10 years, Sudarshan Pharma Industries's highest Return-on-Tangible-Equity was 20.21%. The lowest was 4.89%. And the median was 12.70%.
BOM:543828's Return-on-Tangible-Equity is ranked better than 85.29% of 1570
companies
in the Chemicals industry
Industry Median: 5.88
vs BOM:543828: 17.28
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Sudarshan Pharma Industries Return-on-Tangible-Equity Related Terms
Sudarshan Pharma Industries Return-on-Tangible-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:543828 vs DOW: Return-on-Tangible-Equity Comparison
For the Chemicals subindustry, Sudarshan Pharma Industries's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sudarshan Pharma Industries Return-on-Tangible-Equity vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, Sudarshan Pharma Industries's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Sudarshan Pharma Industries's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 30.40% mean?
Sudarshan Pharma Industries (BOM:543828) has a Return-on-Tangible-Equity of 30.40% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Sudarshan Pharma Industries and its competitors. This is 139% above median its historical median of 12.70. Over the past decade, Sudarshan Pharma Industries' Return-on-Tangible-Equity has ranged from 4.89 to 20.21. According to the industry distribution chart, Sudarshan Pharma Industries ranks #231 out of 1570 companies in the Chemicals industry, placing it in the top 14.7%.
Is Sudarshan Pharma Industries' Return-on-Tangible-Equity too high?
Sudarshan Pharma Industries' current Return-on-Tangible-Equity of 30.40% is 139% above median its 10-year median of 12.70. Over the past 10 years, this metric has ranged from a low of 4.89 to a high of 20.21. The Chemicals industry median Return-on-Tangible-Equity is 5.88. Sudarshan Pharma Industries' value of 30.40% is 417% above this industry median. Based on the distribution chart, Sudarshan Pharma Industries ranks #231 out of 1570 companies in the Chemicals industry, which is in the top quartile — a strong position relative to peers. Overall, Sudarshan Pharma Industries has a GF Score™ of 69/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sudarshan Pharma Industries' Return-on-Tangible-Equity compare to DOW?
According to the Chemicals industry distribution chart, Sudarshan Pharma Industries ranks #231 out of 1570 companies for Return-on-Tangible-Equity. This places Sudarshan Pharma Industries in the top 15% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Equity is 5.88. Sudarshan Pharma Industries' value of 30.40% is 417% above this benchmark. Historically, Sudarshan Pharma Industries' own Return-on-Tangible-Equity has ranged from 4.89 to 20.21 over the past decade. While the company's 10-year median is 12.70 vs. the industry median of 5.88, Sudarshan Pharma Industries has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Chemicals company?
The median Return-on-Tangible-Equity among Chemicals companies is 5.88, based on 1,570 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sudarshan Pharma Industries's current Return-on-Tangible-Equity of 30.40% is 417% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Sudarshan Pharma Industries and its competitors. For the Chemicals industry, the median Return-on-Tangible-Equity is 5.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sudarshan Pharma Industries's current Return-on-Tangible-Equity is 30.40%, which is 139% above median its own 10-year median of 12.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sudarshan Pharma Industries stock overvalued right now?
Based on GuruFocus' analysis, Sudarshan Pharma Industries (BOM:543828) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹6.52, compared to a current price of ₹32.49 — trading 398.3% above its estimated fair value. The current Return-on-Tangible-Equity is 30.40%, which is 139% above median its 10-year median of 12.70 and 417% above the Chemicals industry median of 5.88. Sudarshan Pharma Industries' overall GF Score™ is 69/100 with 14 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Sudarshan Pharma Industries (BOM:543828), the current Return-on-Tangible-Equity is 30.40% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sudarshan Pharma Industries (BOM:543828) Overvalued in 2026?
Based on GuruFocus' analysis, Sudarshan Pharma Industries stock appears to be overvalued.
The current stock price of ₹32.49 is trading 398.3% above its estimated GF Value™ of ₹6.52.
GuruFocus considers Sudarshan Pharma Industries to be Significantly Overvalued.
Key valuation signals for BOM:543828:
Return-on-Tangible-Equity: 30.40% (139% above median its 10-year median of 12.70)
GF Value™: ₹6.52 vs. price of ₹32.49 (398.3% above fair value)
Industry Position: 417% above the Chemicals median (#231 of 1570)
No single metric tells the full story. See the BOM:543828 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sudarshan Pharma Industries Ltd operates in the pharmaceutical and chemical industries, focusing on specialty chemicals and intermediates used in pharmaceuticals, paints, food products, and adhesives. The Company has a presence domestically and internationally, participating regularly in trade fairs and exhibitions. The Company exports mainly to South East Asia, the Middle East, and North Africa. The Company also supplies generic pharmaceutical formulation as 'Make to order' for bulk supply to hospitals and related healthcare organisations. The company has one reportable segment of Specialty Chemicals.
69GF Score
Get the complete analysis for BOM:543828
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:543828 has been successfully added to your 
